Cerecor Inc (CERC) Director Armistice Capital, Llc Acquires 4,586 Shares

Cerecor Inc (NASDAQ:CERC) Director Armistice Capital, Llc acquired 4,586 shares of Cerecor stock in a transaction that occurred on Wednesday, October 31st. The stock was acquired at an average cost of $3.91 per share, with a total value of $17,931.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Armistice Capital, Llc also recently made the following trade(s):

  • On Monday, October 29th, Armistice Capital, Llc acquired 33,292 shares of Cerecor stock. The stock was acquired at an average cost of $3.94 per share, with a total value of $131,170.48.
  • On Friday, October 26th, Armistice Capital, Llc acquired 55,899 shares of Cerecor stock. The stock was acquired at an average cost of $3.94 per share, with a total value of $220,242.06.
  • On Wednesday, October 24th, Armistice Capital, Llc acquired 83,800 shares of Cerecor stock. The stock was acquired at an average cost of $4.06 per share, with a total value of $340,228.00.
  • On Monday, October 22nd, Armistice Capital, Llc acquired 20,000 shares of Cerecor stock. The stock was acquired at an average cost of $4.31 per share, with a total value of $86,200.00.
  • On Monday, October 8th, Armistice Capital, Llc acquired 19,588 shares of Cerecor stock. The stock was acquired at an average cost of $4.33 per share, with a total value of $84,816.04.
  • On Thursday, October 4th, Armistice Capital, Llc acquired 2,015 shares of Cerecor stock. The stock was acquired at an average cost of $4.35 per share, with a total value of $8,765.25.
  • On Thursday, September 27th, Armistice Capital, Llc acquired 6,473 shares of Cerecor stock. The stock was acquired at an average cost of $4.71 per share, with a total value of $30,487.83.
  • On Tuesday, September 25th, Armistice Capital, Llc acquired 9,296 shares of Cerecor stock. The stock was acquired at an average cost of $4.60 per share, with a total value of $42,761.60.

CERC traded down $0.11 during trading on Friday, hitting $4.37. The stock had a trading volume of 50 shares, compared to its average volume of 105,351. The company has a market capitalization of $153.77 million, a PE ratio of 10.57 and a beta of 1.32. Cerecor Inc has a 12 month low of $1.00 and a 12 month high of $5.74. The company has a debt-to-equity ratio of 0.75, a current ratio of 0.62 and a quick ratio of 0.54.

Cerecor (NASDAQ:CERC) last announced its earnings results on Thursday, August 9th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $4.79 million for the quarter, compared to the consensus estimate of $4.50 million. Cerecor had a net margin of 15.71% and a return on equity of 43.87%. Analysts anticipate that Cerecor Inc will post -0.55 earnings per share for the current year.

Separately, ValuEngine raised shares of Cerecor from a “hold” rating to a “buy” rating in a research note on Wednesday, August 29th.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Northern Trust Corp raised its holdings in Cerecor by 182.0% in the 1st quarter. Northern Trust Corp now owns 31,506 shares of the company’s stock worth $135,000 after acquiring an additional 20,333 shares during the period. Spark Investment Management LLC bought a new position in Cerecor in the 2nd quarter worth $288,000. Finally, BlackRock Inc. raised its holdings in Cerecor by 630.4% in the 2nd quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock worth $120,000 after acquiring an additional 23,752 shares during the period. Hedge funds and other institutional investors own 41.59% of the company’s stock.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

See Also: Intrinsic Value and Stock Selection

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply